News Release

Cleanascite™ Cited To Help Determine the Role of Lipids in Supporting Immunosuppressive Neutrophil Differentiation within Tumors

MONMOUTH JUNCTION, NJ, November 4, 2024 -- Biotech Support Group reports on an article, describing the simplicity and efficiency of their lipid clearance sample preparation from cultured primary human neutrophils isolated from the blood of healthy donors with cancer supernatants from various human cancer cell lines. The citation is:

Dahal, Ankit, et al. "Platelet-activating factor (PAF) promotes immunosuppressive neutrophil differentiation within tumors." Proceedings of the National Academy of Sciences 121.35 (2024): e2406748121.

Chronic inflammatory milieu in the tumor microenvironment (TME) leads to the recruitment and differentiation of myeloid- derived suppressor cells (MDSCs). Polymorphonuclear (PMN)- MDSCs, which are phenotypically and morphologically defined as a subset of neutrophils, cause major immune suppression in the TME, posing a significant challenge in the development of effective immunotherapies. Despite recent advances in our understanding of PMN- MDSC functions, the mechanism that gives rise to immunosuppressive neutrophils within the TME remains elusive. Consistent in both in vivo and in vitro systems, newly recruited neutrophils into the tumor sites remained activated and highly motile for several days and developed immunosuppressive phenotypes, as indicated by increased arginase 1 (Arg1) and dcTrail- R1 expression and suppressed anticancer CD8 T cell cytotoxicity. The strong suppressive function was successfully recapitulated by incubating naive neutrophils with cancer cell culture supernatant in vitro. To test the hypothesis that cancer-secreted mediators were lipids, we selectively depleted lipids from the cancer cell supernatant using a lipid-binding micelle kit (Cleanascite™). The article states “To deplete lipids from cancer supernatant, we added Cleanascite reagent (Biotech Support Group) according to the manufacturer’s protocol. Briefly, 1:4 ratio of Cleanascite reagent was added to culture media at room temperature and placed on a rocking platform. After 10 min, the media was centrifuged at 1000×g for 5 min.”




Importantly, depletion of lipids did not change neutrophil activation ( Fig. 4G ) but drastically abrogated the ability of neutrophils to both survive in cancer supernatant and limited the ability of neutrophils to express the MDSC markers, including Arg1 and dcTrail-R1 across both murine and human cancers ( Fig. 4 H and I ). Importantly, the process of lipid depletion did not alter neutrophil survival or activation, suggesting that abrogation of MDSC phenotype is directly the result of depleted cancer secreted lipids. Cancer metabolite secretome analyses of the culture supernatant revealed that both murine and human cancers released lipid mediators to induce the differentiation of immunosuppressive neutrophils. The study identifies platelet-activation factor (PAF) as a lipid-driven mechanism of MDSC differentiation in the tumor microenvironment, providing a potential target for cancer immunotherapy.

“We now have over thirty references, showing Cleanascite™ use in helping to identify a characteristic feature of in vitro cell response. Notably, this is the sixth reference that specifically investigated the role of lipids in phenotype differentiation of innate immune cells in cancer. Unlike alternative lipid-depletion methods that use solvents, Cleanascite™ is an aqueous suspension product and so it is very compatible with cellular models of disease. The essential requirement is the maintenance of cellular activity after lipid depletion, to determine whether lipid factors are associated with phenotypic changes in cultured cells” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Download whitepaper entitled “Cleanascite™ - Lipid Removal and Cell Response Applications”, visit:

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

Keywords: Lipid depletion, lipid metabolism, Cleanascite™, Tumor microenvironment, Myeloid-derived suppressor cells (MDSC), immunosuppressive neutrophil phenotype

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for targeted proteomics and family specific proteome enrichment. For more information, go to http://www.biotechsupportgroup.com.

For Business Development, contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com